LADENBURG THALM/SH SH Downgrades Marinus Pharmaceuticals (NASDAQ:MRNS) to Neutral

LADENBURG THALM/SH SH lowered shares of Marinus Pharmaceuticals (NASDAQ:MRNS) from a buy rating to a neutral rating in a report published on Wednesday, Marketbeat.com reports.

Other equities research analysts have also recently issued reports about the company. HC Wainwright reissued a buy rating and set a $11.00 price target on shares of Marinus Pharmaceuticals in a report on Tuesday, June 18th. Truist Financial reissued a buy rating and issued a $10.00 price target on shares of Marinus Pharmaceuticals in a report on Tuesday, June 18th. Finally, Robert W. Baird reaffirmed a neutral rating on shares of Marinus Pharmaceuticals in a report on Tuesday, April 16th. Five analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of Hold and an average target price of $12.75.

Marinus Pharmaceuticals Stock Up 3.3 %

MRNS stock opened at $1.26 on Wednesday. The business’s 50-day moving average price is $1.33 and its 200-day moving average price is $4.30. The stock has a market cap of $69.22 million, a P/E ratio of -0.48 and a beta of 1.13. Marinus Pharmaceuticals has a twelve month low of $1.05 and a twelve month high of $11.26. The company has a quick ratio of 2.93, a current ratio of 3.07 and a debt-to-equity ratio of 5.68.

Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.01). The firm had revenue of $8.06 million for the quarter, compared to analysts’ expectations of $9.05 million. Marinus Pharmaceuticals had a negative net margin of 513.80% and a negative return on equity of 518.13%. During the same period in the prior year, the firm earned ($0.61) EPS. On average, equities research analysts forecast that Marinus Pharmaceuticals will post -1.87 EPS for the current year.

Institutional Trading of Marinus Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of MRNS. SG Americas Securities LLC purchased a new stake in shares of Marinus Pharmaceuticals in the fourth quarter valued at $134,000. Wellington Management Group LLP grew its stake in shares of Marinus Pharmaceuticals by 54.8% during the fourth quarter. Wellington Management Group LLP now owns 241,299 shares of the biopharmaceutical company’s stock valued at $2,623,000 after buying an additional 85,455 shares during the last quarter. abrdn plc purchased a new stake in shares of Marinus Pharmaceuticals in the fourth quarter worth approximately $6,006,000. Vanguard Group Inc. lifted its stake in shares of Marinus Pharmaceuticals by 5.0% during the 1st quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock worth $25,366,000 after acquiring an additional 132,689 shares during the last quarter. Finally, Trexquant Investment LP purchased a new position in Marinus Pharmaceuticals during the 4th quarter valued at $553,000. Hedge funds and other institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.